Efficacy of Tiotropium in Patients of African Descent With Chronic Obstructive Pulmonary Disease
NCT ID: NCT00106821
Last Updated: 2013-11-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
166 participants
INTERVENTIONAL
2004-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tiotropium Bromide Inhalation Powder
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 40 years of age or older
* Diagnosis of COPD
* History of smoking at least one pack per day for at least 10 years
* Currently experiencing shortness of breath at least with exertion
Exclusion Criteria
* Recent myocardial infarction or hospitalization for congestive heart failure
40 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Boehringer Ingelheim
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Boehringer Ingelheim Study Coordinator
Role: STUDY_CHAIR
Boehringer Ingelheim
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Boehringer Ingelheim Investigational Site
Birmingham, Alabama, United States
Cooper Green Hospital
Birmingham, Alabama, United States
University of Alabama at Birmingham
Birmingham, Alabama, United States
David Geffen School of Medicine
Los Angeles, California, United States
VA Greater Los angeles Health Care Systems
Sepulveda, California, United States
Boehringer Ingelheim Investigational Site
Waterbury, Connecticut, United States
Yale Univ. Pulmonary and Critical Care Medicine
West Haven, Connecticut, United States
Emerald Coast Research Associates
Panama City, Florida, United States
Bay Pines V. A. Medical Center
Saint Petersberg, Florida, United States
Louisiana State University School of Medicine
New Orleans, Louisiana, United States
LSU MC-Sheveport
Shreveport, Louisiana, United States
Bronx VA Medical Center
The Bronx, New York, United States
Brody School of Medicine, East Carolina University
Greenville, North Carolina, United States
Boehringer Ingelheim Investigational Site
Philadelphia, Pennsylvania, United States
Temple University Hospital
Philadelphia, Pennsylvania, United States
Boehringer Ingelheim Investigational Site
Charleston, South Carolina, United States
Spartanburg Medical Research
Spartanburg, South Carolina, United States
Attention: Amir Sharafkhaneh, M.D.
Houston, Texas, United States
VAMC Houston
Houston, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
205.294
Identifier Type: -
Identifier Source: org_study_id